Key points are not available for this paper at this time.
Dear Editor, cervical cancer is the fourth most frequent malignancy and the leading cause of cancer death in women worldwide, despite being highly preventable.1 In developing countries in Africa and Asia, there is a high incidence of cervical cancer.1 As earlier noted, cervical cancer frequently ranks as the top cause of cancer-related morbidity and mortality in low-income nations.1 In clinical oncology, the control of the cervix cancer is an important issue for cancer prevention. Several preventive measures including cervical cytology screening and vaccination are practiced. Several screening methods such as cytology and human papillomavirus (HPV) deoxyribonucleic acid (DNA) are available at present.1 Cervical cancer vaccination is currently used as standard practices. The worldwide regular vaccination program for all females aged 12 to 16 now includes HPV vaccine.
Kleebayoon et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: